SHANGHAI MICURX PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.35 CNY | -0.23% |
|
+1.16% | -33.38% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Shanghai MicuRx Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development (R&D) and commercialization of innovative drugs. The Company's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The Company also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The Company operates its businesses primarily in the domestic market.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.35
CNY
Average target price
6.875
CNY
Spread / Average Target
+58.05%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.38% | 392M | |
| +55.55% | 816B | |
| +39.59% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.06% | 238B | |
| +1.19% | 222B | |
| +13.77% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- 688373 Stock
- News Shanghai MicuRx Pharmaceutical Co., Ltd.
- MicuRx Pharma's Phase 1 China Trial for Polymyxin Antibiotic Shows Good Safety Profile
